ARTICLE | Clinical News

Twynsta telmisartan/amlodipine: Phase III data

September 6, 2010 7:00 AM UTC

In a double-blind Phase III trial in 858 patients with severe hypertension, an 80/10 mg formulation of Twynsta telmisartan/amlodipine met the primary endpoint of a significantly greater reduction from baseline in mean seated SBP at week 8 vs. 80 mg telmisartan alone (p<0.0001) and 10 mg amlodipine alone (p=0.0002). Additionally, 46% of Twynsta-treated patients achieved a >=50 mmHg reduction in blood pressure. Twynsta also significantly reduced SBP from baseline vs. telmisartan and amlodipine monotherapies at weeks 2, 4 and 6 (p<0.0001 for all), and significantly reduced diastolic blood pressure (DBP) from baseline vs. telmisartan monotherapy at weeks 1, 2, 4, 6 and 8 (p<0.0001 for all). Twynsta was well tolerated. Data were presented at the European Society for Hypertension meeting in Oslo in June. ...